Đang chuẩn bị liên kết để tải về tài liệu:
Continual reassessment method for dose escalation clinical trials in oncology: A comparison of prior skeleton approaches using AZD3514 data

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

The continual reassessment method (CRM) requires an underlying model of the dose-toxicity relationship (“prior skeleton”) and there is limited guidance of what this should be when little is known about this association. In this manuscript the impact of applying the CRM with different prior skeleton approaches and the 3 + 3 method are compared in terms of ability to determine the true maximum tolerated dose (MTD) and number of patients allocated to sub-optimal and toxic doses. |

TÀI LIỆU LIÊN QUAN

A web tool for designing and conducting phase I trials using the continual reassessment method

Assessment of various continual reassessment method models for doseescalation phase 1 oncology clinical trials: Using real clinical data and simulation studies

Determination of the ED95 of intrathecal hyperbaric prilocaine with sufentanil for scheduled cesarean delivery: A dose-finding study based on the continual reassessment method

Continual reassessment method for dose escalation clinical trials in oncology: A comparison of prior skeleton approaches using AZD3514 data

A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.